Labeling shift for Lily's Evista approved
The U.S. Food and Drug Administration approved a package-labeling change for Eli Lilly & Co.'s osteoporosis drug Evista that will allow the company's sales personnel to refer to research studies
The U.S. Food and Drug Administration approved a package-labeling change for Eli Lilly & Co.'s osteoporosis drug Evista that will allow the company's sales personnel to refer to research studies